Category: BPH
Introduction & Objective :
Endoscopic enucleation of the prostate is currently the first treatment option in patients with BPH over 80 cc. However, enucleation in cases of giant-sized glands (>200cc) is believed to potentially be a more complicated and time-consuming procedure.
Methods : Our retrospective study included 13 patients aged 67.2 (54-89) years with infravesical obstruction (IPSS>20, Qmax<10) due to BPH, who underwent HoLEP. Patients with urethral strictures, bladder stones, acute inflammation of the genitourinary tract or a history of prior prostate surgery were excluded. For enucleation, we used VersaPulse (Lumenis, Israel) with a 550 µm laser fiber. Tissue removal from the bladder was performed with the help of a Piranha morcellator (Richard Wolf, Germany). Preoperatively and six months after surgery we evaluated IPSS, QoL, Qmax and post-void residual volume. All statistical analyses were performed using SPSS Statistics 22.0 (SPSS Inc., Chicago, IL, USA). A p-value of 0.05 was chosen as a threshold for statistical significance.
Results :
Mean BPH volume was 217.1 cc (200-250 cc). Mean surgery time was 148.1±19.3 and a mean mass of removed tissue was 171.2 g. Catheterization time was 32.4 hours and hospital stay was 3.4 (3-4) days. After removal of urethral catheter, 2 (15.4%) patients had de novo stress urinary incontinence, urgency was observed in 1 patient (7.7%). At 6 months, there were no patients with stress urinary incontinence. There were one case of clot retention and one case of urinary infection. Six months after surgery, we observed a statistically significant improvement in IPSS, QoL, Qmax and post-void residual volume in all the patients (p
Conclusions :
Endoscopic enucleation is a safe treatment option for BPH over 200 cc with reliable functional outcomes up to 2 years after surgery. Rate of postoperative complications after HoLEP of giant BPH did not exceed that of HoLEP for 80-200cc glands. Endoscopic enucleation requires short hospital stay and catheterization duration and allows for fast return to normal life.
Dmitry Enikeev
– Deputy Director for Science, Institute for Urology and Reproductive health, Sechenov University, Moscow, Moskva, RussiaLeonid Rapoport
– Deputy Director, RI for Uronephrology, Sechenov University, Moscow, Moskva, RussiaMark Taratkin
– Researcher, Institute for Urology, Sechenov University, Moscow, Moskva, RussiaDeputy Director for Science
Institute for Urology and Reproductive health, Sechenov University
Moscow, Moskva, Russia
Surgical experience:
Experienced in TURP (>300 surgeries).
Experienced in upper urinary tract endosurgery (PCNL >200, RIRS >200).
2008-Present: Multiple upper and lower urinary tract surgeries;
2011-Present: HoLEP (400 surgeries);
2011-Present: En-bloc enucleation of bladder tumor (50 surgeries);
2016-Present: ThuLEP (>400 surgeries);
2016-Present: Thulium en-bloc enucleation of bladder tumor (>80 surgeries);
2016-Present: Brachytherapy (>40 surgeries); prostate cryoablation (70 surgeries), renal cancer cryoablation (30 surgeries);
Apr 2017-Present: Irreversible electroporation (10 surgeries);
Apr 2017-Present: MR-fusion prostate biopsy (80 procedures).
Deputy Director
RI for Uronephrology, Sechenov University
Moscow, Moskva, Russia